stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) Operating cash flow
Adaptive Biotechnologies Corporation's operating cash flow for fiscal 2025 was −$46.0M, compared with −$95.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$4.3M. Over the past ten years it has ranged from −$192.7M (fiscal 2021) to $205.4M (fiscal 2019); the current reading is higher than 67% of that period. Operating cash flow has risen for 4 consecutive fiscal years. Adaptive Biotechnologies Corporation ranks 31st of 49 Diagnostics & Research companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$46.0M | — |
| FY2024 | −$95.2M | — |
| FY2023 | −$156.3M | — |
| FY2022 | −$183.9M | — |
| FY2021 | −$192.7M | — |
| FY2020 | −$149.7M | — |
| FY2019 | $205.4M | — |
| FY2018 | −$32.3M | — |
| FY2017 | −$34.9M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $9.6M | — |
| Jun 2026 | −$6.4M | — |
| Mar 2026 | −$9.5M | — |
| Dec 2025 | $2.1M | — |
| 31 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SHC Sotera Health Company compare | $331.6M |
| RDNT RadNet, Inc. compare | $310.1M |
| VCYT Veracyte, Inc. compare | $173.9M |
| CDNA CareDx, Inc. compare | $69.0M |
| BLLN BillionToOne, Inc. compare | $47.9M |
| NEO NeoGenomics, Inc. compare | $4.3M |
| ADPT Adaptive Biotechnologies Corporation | −$4.3M |
| WGS GeneDx Holdings Corp. compare | −$48.7M |
| GRAL GRAIL, Inc. compare | −$306.2M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on ADPT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement